What Happened?
Shares of clinical research company Medpace Holdings (NASDAQ: MEDP) fell 7.5% in the afternoon session after an analyst at TD Cowen downgraded the stock to "Sell" from "Hold," citing valuation concerns following a massive rally in the previous session.
The downgrade came just one day after Medpace's stock surged approximately 55% on the back of strong second-quarter earnings that surpassed analyst expectations. The company reported revenue of $603.3 million and earnings per share of $3.10, beating forecasts.
However, the TD Cowen analyst suggested the prior day's dramatic price increase was primarily due to short covering—where investors who bet against a stock are forced to buy shares to close their positions—rather than fundamental business improvements. Despite raising the price target to $366 from $283, the firm expressed concern that Medpace's shares appeared overvalued relative to its expected growth. The analyst noted that while the outlook for bookings and revenue had improved, the current valuation was too high. This assessment overshadowed the strong quarterly results and the company's increased full-year guidance, prompting a pullback in the stock.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Medpace? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Medpace’s shares are quite volatile and have had 17 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 1 day ago when the stock gained 49.3% on the news that the company reported strong second-quarter financial results and raised its full-year guidance. The company announced its second-quarter results, revealing revenue of $603.3 million, a 14.2% increase from the prior-year period. Earnings per share also grew, coming in at $3.10. Following the strong performance, Medpace raised its full-year 2025 revenue forecast to a range of $2.42 billion to $2.52 billion. It also increased its earnings per share guidance for the year to a range of $13.76 to $14.53. This positive outlook, which surpassed previous forecasts, appeared to fuel significant investor optimism.
Medpace is up 29.9% since the beginning of the year, and at $434.75 per share, it is trading close to its 52-week high of $477.73 from July 2025. Investors who bought $1,000 worth of Medpace’s shares 5 years ago would now be looking at an investment worth $3,926.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
